SCHEMBL7595327

SCHEMBL7595327

C=Cc1ccc(F)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
GABRA1 P14867 1/20 0.44
SIGMAR1 Q99720 1/20 0.44
ALDH1A1 P00352 3/20 0.43
NFE2L2 Q16236 1/20 0.41
PTGS1 P23219 3/20 0.38
PTGS2 P35354 3/20 0.38
ALOX5 P09917 2/20 0.38
TRPA1 O75762 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
TUBB1 Q9H4B7 2/20 0.38
ACHE P22303 1/20 0.37
MAPK14 Q16539 2/20 0.36
MAPT P10636 1/20 0.34
PKM P14618 1/20 0.34
TSHR P16473 2/20 0.33
LMNA P02545 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13614803 0.82 TP53 (0.45) TP53TDP1ALDH1A1NFE2L2PTGS1
SCHEMBL2088615 0.78 NFE2L2 (0.47) GABRA1SIGMAR1NFE2L2PTGS1PTGS2
SCHEMBL2088613 0.78 NFE2L2 (0.47) GABRA1SIGMAR1NFE2L2PTGS1PTGS2
SCHEMBL293173 0.78 ALDH1A1 (0.50) TP53TDP1ALDH1A1PTGS1PTGS2
SCHEMBL29407001 0.78 ALDH1A1 (0.50) TP53TDP1ALDH1A1PTGS1PTGS2
SCHEMBL248639 0.78 NFE2L2 (0.50) TP53TDP1ALDH1A1NFE2L2PTGS2
SCHEMBL29662132 0.78 NFE2L2 (0.50) TP53TDP1ALDH1A1NFE2L2PTGS2
SCHEMBL336067 0.77 ALDH1A1 (0.47) TDP1GABRA1SIGMAR1ALDH1A1NFE2L2
SCHEMBL16958944 0.77 GABRA1 (0.47) GABRA1SIGMAR1NFE2L2PTGS1PTGS2
SCHEMBL9996728 0.77 GABRA1 (0.44) GABRA1SIGMAR1ALDH1A1NFE2L2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113493450-B Ligand compound, preparation method thereof and application thereof in asymmetric reaction 中国科学院福建物质结构研究所 2023-07-25 CN disclosed
US-11661397-B2 1,4-disubstituted imidazole derivative Sumitomo Pharma Co., Ltd. (JP) 2023-05-30 US disclosed
EP-4112606-A1 AROMATIC COMPOUND AND USE THEREOF IN PREPARING ANTINEOPLASTIC DRUGS Shanghai Zheye Biotechnology Co., Ltd. (CN) 2023-01-04 EP disclosed
CN-113493450-A Ligand compound, preparation method thereof and application thereof in asymmetric reaction 中国科学院福建物质结构研究所 2021-10-12 CN disclosed
CN-113461721-A BODIPY near-infrared fluorescent dye with large Stokes shift and preparation method thereof 南京林业大学 2021-10-01 CN disclosed
EP-3673908-A1 ANTI-TUMOR EFFECT POTENTIATOR Taiho Pharmaceutical Co., Ltd. (JP) 2020-07-01 EP disclosed
CN-109923114-A Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer 因赛特公司 2019-06-21 CN disclosed
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2018-07-12 US disclosed
US-9828362-B2 1,4-disubstituted imidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2017-11-28 US disclosed
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2017-06-15 US disclosed
EP-2909192-B1 METHYLENE LINKED QUINOLINYL MODULATORS OF ROR-GAMMA-T JANSSEN PHARMACEUTICA NV (BE) 2017-05-17 EP disclosed
EP-2900645-A1 3-PHENYLISOXAZOLIN DERIVATIVES WITH HERBICIDAL ACTION Bayer CropScience AG (DE) 2015-08-05 EP disclosed
CN-104812790-A Organopolysiloxane graft polymer KAO CORP 2015-07-29 CN disclosed
US-8895565-B2 Heterocyclic compound and use of the same NISHIO TETSUYA (JP) 2014-11-25 US disclosed
US-20110319618-A1 HETEROCYCLIC COMPOUND AND USE OF THE SAME NISHIO TETSUYA (JP) 2011-12-29 US disclosed
EP-0745473-B1 Oriented film including polystyrene polymer having syndiotactic configuration TOYO BOSEKI (JP) 2002-12-11 EP disclosed
US-5707719-A Oriented film including polystyrene polymer having syndiotactic configuration TOYO BOSEKI KABUSHIKI KAISHA (JP) 1998-01-13 US disclosed
EP-0745473-A2 Oriented film including polystyrene polymer having syndiotactic configuration Toyo Boseki Kabushiki Kaisha (JP) 1996-12-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166552-A1 1,4-DISUBSTITUTED IMIDAZOLE DERIVATIVE NR4A3, NR0B1, NR2C2 TP53 247/4885TDP1 4690/4885GABRA1 1692/4885
US-20110319618-A1 HETEROCYCLIC COMPOUND AND USE OF THE SAME CYP2D6, CYP2B6, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 TP53 3457/4885TDP1 4545/4885GABRA1 1156/4885
US-11661397-B2 1,4-disubstituted imidazole derivative NR4A3, NR0B1, NR2C2 TP53 247/4885TDP1 4690/4885GABRA1 1692/4885
US-20180194773-A1 BICYCLIC HETEROCYCLIC AMIDE DERIVATIVE NR0B1, NR2E1, NR0B2 TP53 396/4885TDP1 4583/4885GABRA1 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.